Systemic Lupus Erythematosus Treatment Market Opportunity Analysis 2018-2026

Systemic Lupus Erythematosus (SLE) is chronic autoimmune disorder. It is characterized by excess production of the antibodies that attacks body’s own cells and vital organs. Various symptoms associated with the disease includes joint pain, swelling, rashes over face (butterfly rash) and other body area, severe fatigue, hair loss, anemia, and Raynaud’s phenomenon etc. SLE can also affect vital body organs such as heart, kidney, lungs, and behavioral changes. Exact causes of the disease is unknown, however, hereditary and environmental factors could be lead to SLE.

Click To Continue Reading on Systemic Lupus Erythematosus Treatment Market

There is no direct cure available for SLE, however, symptomatic treatment can be administered to lower or eliminate symptoms associated with disease. Major classes of drugs commonly used are antimalarial agents such as chlorquine and hydrochlorquine; topical steroid cream for rashes; NSAIDS for joint pain; and fever steroidal medication such as glucocorticoids through IV or oral route and immunosuppressive agents to lower immune response from the antibodies.

Rise in incidence of SLE is one of major factors driving growth of the systemic lupus erythematosus treatment market. According to study published in the Expert Review of Clinical Immunology in 2017, the global incidence rate varied from about 0.3–23.7 per 100,000 person and the prevalence rates varied in the range from 6.5 to 178.0 per 100,000 people. Key companies are entering into collaborations for research and development in systemic lupus erythematosus, which is expected to support growth of the market.

For instance, in 2015, a genomic mapping company, 23andMe, Inc. collaborated with Pfizer, Inc. to study and understand the genetics of lupus thereby, to develop treatment for it. In 2012, Alliance for Lupus Research and Pfizer’s Centers for Therapeutic Innovation collaborated to discover new therapies for patients living with systemic lupus erythematosus. Increasing approvals for products for the treatment of SLE is another factor expected to aid in growth of the market. For instance, GlaxoSmithKline, in July 2017, received U.S.FDA approval for the subcutaneous form of its biologic drug belimumab for treatment of systemic lupus erythematosus. Clinical guidelines to include biologics in the treatment of systemic lupus erythematosus would further aid in market growth.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1540

Key Vendors:

GlaxoSmithKline Plc (GSK), F. Hoffmann-La Roche Ltd, Anthera Pharmaceuticals Inc., Bristol-Myers Squibb, Eli Lilly, Pfizer Limited, Merck KGaA, Immupharma Plc, Sanofi, Lycera Corporation, Aurinia Pharmaceuticals Inc., Mylan N.V., and Sandoz International GmbH.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

Working as Sr. Seo With Adroit Market Research